

# American Liver Foundation



## IMPACT REPORT 2020-2021



Even during the difficult times, we are here for you.  
Thank you for being there for us.

# A LETTER FROM OUR LEADERSHIP

Fall 2021

Dear Friends and Colleagues,

On behalf of the American Liver Foundation (ALF) National Board of Directors and ALF National Staff, we thank you for your ongoing support.

This 2020 ALF Impact Report acknowledges the transformational changes that were required to navigate this organization through the early months of the pandemic. Thankfully, the changes made in 2020 enabled us to end the year on solid financial footing. In 2021, we continue to re-envision ALF – creating an even stronger and more effective organization for the benefit of the liver community.


Individuals with liver disease - their caregivers, loved ones, friends and colleagues - remain the center of the ALF universe. Even during these challenging 18 months of COVID, our programmatic activities remained strong. We were there for you.

Please accept our deepest gratitude for everything you do to support our life-saving mission. Your generosity empowers our dedicated team of volunteers and staff to generate vital education, support services, advocacy, and research for the benefit of patients and their families.

With great appreciation,



Dan Weil  
Chair, National Board of Directors



Lorraine Stiehl  
Chief Executive Officer





## COVID-19 RESPONSE

### Pivoting During the Pandemic

People with liver disease have an elevated risk for COVID-19 and, should they contract the virus, suffer more severe complications. ALF quickly created webinars, educational videos, and blog posts to inform patients and caregivers on the potential risks. Examples included webinars with infectious disease specialists, videos on COVID-19 and liver transplantation, healthy eating at home, and much more.

## SUPPORT BY THE NUMBERS

**12**

languages available for patient and caregiver education on our website

**16**

minutes engaged on our most popular webpages - with all pages averaging 4.5 minutes

**870**

early-career researchers who received over \$27 million through ALF's award program to date

**8,000**

inquiries received by our free ALF Helpline

**64,000**

downloads of our online brochures

**235,000**

people following our social media channels

**355,000**

annual webpage views of liver disease diets

**464,000**

blog post views of "13 ways to a healthy liver"

**753,000**

views of our "Progression of Liver Disease" webpage



## IMPACT THROUGH PUBLIC AWARENESS

Because of your generosity



The **NASHional CONVERSATION**<sup>®</sup> focuses on nonalcoholic steatohepatitis (NASH), a rising health epidemic impacting up to 12% of U.S. adults. It launched in 2020 in English and Spanish.



Take a short quiz to see if you're at risk



Talk to your doctor about screening options

**GREATEST GIFT INITIATIVE** campaign debuted in 2020. This important initiative not only informs people about living donor liver transplantation (LDLT), it helps individuals who are seeking a donor to learn how to begin the conversation. Our virtual information center provides comprehensive and up-to-date education, an easy-to-use digital toolkit on starting the LDLT process, patient videos and more.



## IMPACT THROUGH ADVOCACY

Because of your generosity

### National Patient Advisory Committee (NPAC)

As a patient-centered organization, we value the voices of patients and caregivers from a range of liver conditions. Our NPAC members improve the lives of all people affected by liver disease by sharing their stories.



NPAC engages with national and community leaders to advocate on issues critical to the liver community.



NPAC raises awareness among the general public and helps people cope with their liver disease.



### ADVOCACY WEEK

Well over 100 advocates met virtually with elected officials and staff during the pandemic to share their stories and discuss ALF's advocacy agenda.



10,000 individuals participated in our annual email-based advocacy campaign.



Patient advocates joined listening sessions with FDA employees and spoke on FDA panels and at hearings.



# IMPACT THROUGH EDUCATION

Because of your generosity

## Equipping patients, caregivers and providers with knowledge



We brought thousands of patients, caregivers and providers together through virtual events to share their knowledge, stories and learn from one another.

- Ask the Experts
- Liver Cancer Conference
- Academic Debates
- Medical Advisory Council Meetings

### PROVIDER EDUCATION

In addition to traditional education opportunities through webinars and Continuing Medical Education classes, ALF engaged providers through innovative programs like the Academic Debates, Mock Liver Tumor Boards, and regional Medical Advisory Board meetings.

### COVID-19 RESPONSE

People with liver disease have an elevated risk for COVID-19 infection and more severe complications. Since the start of the pandemic, over two million patients and health care professionals accessed our virtual education, information, and support services. COVID-19 specific content covered topics like transplantation, caregiving, healthy eating at home, and disease specific information.



*"I learned more from you today than I did when I visited my doctor and read the pamphlet she gave me. You provided me very important information concerning my health and safety and for that, I thank you so very much."*

- Anonymous Helpline Caller  
July 2020





## IMPACT THROUGH CLINICAL TRIAL AWARENESS

Because of your generosity



### CLINICAL TRIALS

People with liver disease understand the importance of research, but not all understand the importance of participation in clinical trials – particularly among diverse audiences. ALF is changing that.



Social media awareness campaigns



[Enhanced Clinical Trials webpage](#)



## IMPACT THROUGH DIVERSITY, EQUITY, INCLUSION

Because of your generosity

### DEI COUNCIL

Our newly established DEI Council will expedite our ability to bridge the gap in healthcare and address health disparities, nationwide. Our hope is to achieve greater diversity, equity and inclusion in the liver community.

**L**eadership  
**I**ntegrity  
**V**igilance  
**E**xcellence  
**R**espect



When we got the devastating news that our infant daughter was diagnosed with a life-threatening liver disease called Biliary Atresia, we needed immediate information, resources, and support to guide us through all the decisions, treatments, tears and fears. We support ALF because they provide education, resources, and mentor support to families facing a liver-health crisis. Our hope is that all families that are facing a similar scary diagnosis will, with ALF's help, have the same positive outcome that we had for our daughter Sadie.

- Bakari and Ellen Sellers

# 2020 FINANCIALS

*Committed to accountability and financial transparency*

*COVID-19 compelled ALF to reorganize, reduce expenses and prioritize investment in mission-focused virtual activities.*


**Total Revenue & Public Support**

\$5,680,000


**Total Assets**

\$5,774,000

**PROGRAM SERVICES**  
\$4.5 million



**SUPPORT & PROGRAM EXPENSES**  
\$5.9 million



# 2020 NATIONAL MEDICAL ADVISORY COUNCIL

Ghassan Abou-Alfa, MD

Talal Adhami, MD, HCMBA, AGAF

Jasmohan Bajaj, MD, MS, FACG, AGAF

Terry Box, MD

Robert Brown, MD, MPH, FAASLD

Douglas Dieterich, MD

Udeme Ekong, MD, MPH, FAASLD

Scott Fink, MD

Catherine Frenette, MD, FAST, AGAF

John Goff, MD

Uma Goyal, MD

Jennifer Guy, MD

Blaine Hollinger, MD

Mary Ann Huang, MD

Alicia Mavis, MD

Nadia Ovchinsky, MD, MBA

Dan Pratt, MD

Kamran Qureshi, MD

Nancy Reau, MD

Chakadhar Reddy, MD

Sammy Saab, MD, MPH, AGAF  
National Medical Advisory  
Council Co-Chair

Adnan Said, MD

Arun Sanyal, MD

Rohit Satoskar, MD

Gabriel Schnickel, MD, MPH, FACS

Coleman Smith, MD

Tamar Taddei, MD  
National Medical Advisory  
Council Co-Chair

Hillel Tobias, MD, PhD

John Vierling, MD, FACP, FAASLD

Rocky Yapp, MD, MPH, AGAF

Bobby Zervos, DO

## 2020 CORPORATE COUNCIL

### GOLD

abbvie



Intercept

Allergan

EXELIXIS

Mallinckrodt  
Pharmaceuticals

CVS specialty

GILEAD

Salix  
Pharmaceuticals

### SILVER

Bristol Myers Squibb

Lincoln  
Financial Group

CYMABAY  
THERAPEUTICS

Pfizer

### BRONZE

Albireo

deep  
genomics



# 2020 FOUNDATION GOVERNANCE

## 2020 BOARD OF DIRECTORS

Daniel E. Weil  
National Board Chair  
Executive Committee Chair

Mike Braunstein  
Audit Committee Chair

Bob Brickman

Eugene Cautillo  
Secretary

Eddie C. Cheung, M.D., FACG

Nicholas J. DeRoma

Allan J. Doerr

T. Clark Gamblin, MD, MS

Mary Ann Huang

Michael Kerr  
Finance Committee Chair

Elizabeth Leesmann

Rohit Loomba, MD, MH Sc

Thomas F. Nealon III

Sammy Saab, MD, MPH, AGAF, FAASLD, FACG  
National Medical Advisory Council Co-Chair

Nicole Smith, PhD  
Development Committee Chair

Susan Sherman Stone, CPA, MST  
Treasurer

Emmanuel Thomas, MD, PhD  
Nominating Committee Chair

Traci Tigie

Hillel Tobias, MD, PhD

Rockford G. Yapp, MD

## 2020 EXECUTIVE TEAM

### Thomas Nealon

Chief Executive Officer  
President

### Lynn Seim


Chief Operating Officer  
Executive Vice President

### David Ticker

Chief Financial Officer  
Executive Vice President

### Lorraine Stiehl

Consultant  
Chief Executive Officer Elect



*Virtual Liver Life Walk 2020*



*Virtual Cuisine for a Cause 2020*



*Your Liver. Your Life.*

American Liver Foundation  
PO Box 299 | West Orange, NJ 07052  
1-800-GO-LIVER  
liverfoundation.org

The American Liver Foundation is a 501(c)3 nonprofit organization.

## CONNECT WITH US!

